Latest Insider Transactions at Syndax Pharmaceuticals Inc (SNDX)
This section provides a real-time view of insider transactions for Syndax Pharmaceuticals Inc (SNDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Syndax Pharmaceuticals Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Syndax Pharmaceuticals Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Keith A. Goldan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+2.32%
|
$25,000
$20.03 P/Share
|
|
Feb 07
2024
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Feb 07
2024
|
Martin H. Huber Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+25.76%
|
-
|
|
Feb 07
2024
|
Neil Gallagher President, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
47,813
+35.77%
|
-
|
|
Feb 07
2024
|
Keith A. Goldan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,700
+32.71%
|
-
|
|
Feb 07
2024
|
Michael A Metzger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
146,250
+32.71%
|
-
|
|
Feb 07
2024
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Feb 07
2024
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+19.34%
|
-
|
|
Feb 07
2024
|
Briggs Morrison |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+32.8%
|
-
|
|
Feb 07
2024
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Feb 07
2024
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Jan 31
2024
|
Keith A. Goldan Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
1,183
+20.2%
|
$20,111
$17.42 P/Share
|
|
Aug 09
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$951,390
$18.27 P/Share
|
|
Aug 09
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$422,840
$8.77 P/Share
|
|
Aug 02
2023
|
William Meury |
SELL
Open market or private sale
|
Direct |
83,000
-36.28%
|
$1,660,000
$20.46 P/Share
|
|
Aug 02
2023
|
William Meury |
BUY
Exercise of conversion of derivative security
|
Direct |
83,000
+26.55%
|
$664,000
$8.15 P/Share
|
|
Jul 31
2023
|
Keith A. Goldan Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
862
+19.81%
|
$15,516
$18.12 P/Share
|
|
Jul 10
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$1,057,100
$20.4 P/Share
|
|
Jul 10
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$422,840
$8.77 P/Share
|
|
Jun 13
2023
|
Keith A. Goldan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
577
-18.0%
|
$12,694
$22.31 P/Share
|
|
Jun 09
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-48.05%
|
$1,109,955
$21.18 P/Share
|
|
Jun 09
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+32.63%
|
$369,985
$7.58 P/Share
|
|
May 09
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$1,109,955
$21.41 P/Share
|
|
May 09
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$317,130
$6.38 P/Share
|
|
Apr 10
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$1,004,245
$19.53 P/Share
|
|
Apr 10
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$317,130
$6.38 P/Share
|
|
Mar 13
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,854
-74.77%
|
$1,162,788
$22.53 P/Share
|
|
Mar 13
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,854
+42.78%
|
$317,124
$6.38 P/Share
|
|
Feb 15
2023
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$625,000
$25.84 P/Share
|
|
Feb 15
2023
|
Peter Ordentlich Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$150,000
$6.79 P/Share
|
|
Feb 06
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,854
-74.77%
|
$1,374,204
$26.83 P/Share
|
|
Feb 06
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,854
+42.78%
|
$317,124
$6.38 P/Share
|
|
Feb 06
2023
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,959
-25.23%
|
$160,893
$27.64 P/Share
|
|
Feb 06
2023
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,959
+20.15%
|
$35,754
$6.38 P/Share
|
|
Feb 02
2023
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Feb 02
2023
|
Martin H. Huber Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2023
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+22.9%
|
-
|
|
Feb 02
2023
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Feb 02
2023
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Feb 02
2023
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Feb 01
2023
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
69
-100.0%
|
$1,932
$28.43 P/Share
|
|
Jan 31
2023
|
Peter Ordentlich Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
69
+50.0%
|
$1,173
$17.32 P/Share
|
|
Jan 13
2023
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
15,000
-18.66%
|
$405,000
$27.0 P/Share
|
|
Jan 13
2023
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+15.57%
|
$195,000
$13.58 P/Share
|
|
Jan 12
2023
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
24,000
-42.86%
|
$624,000
$26.74 P/Share
|
|
Jan 12
2023
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+30.0%
|
$216,000
$9.47 P/Share
|
|
Dec 02
2022
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
17,200
-98.48%
|
$430,000
$25.05 P/Share
|
|
Dec 02
2022
|
Peter Ordentlich Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,200
+49.62%
|
$103,200
$6.38 P/Share
|
|
Dec 01
2022
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,800
-93.63%
|
$195,000
$25.01 P/Share
|
|
Dec 01
2022
|
Peter Ordentlich Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,800
+48.36%
|
$46,800
$6.37 P/Share
|